Elagolix in endometriosis
Two randomized phase III trials demonstrated that elagolix, an oral GnRH receptor antagonist, significantly reduced endometriosis-associated pain, including dysmenorrhea and non-menstrual pelvic pain, compared to placebo.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This paper discusses the results of two randomized phase III trials (Elaris Endometriosis I and II) evaluating elagolix, an oral GnRH receptor antagonist, in women with moderate or severe endometriosis-associated pain. Across 6 months of treatment, elagolix at low dose (150 mg once daily) or high dose (200 mg twice daily) was compared with placebo, with primary endpoints defined as clinical response at 3 months based on reductions in dysmenorrhoea and non-menstrual pelvic pain scores and decreased or stable rescue analgesic use. The key finding reported is that elagolix reduces pain symptoms versus placebo. The paper notes that effective pain management options remain limited, but it provides the efficacy and safety evidence as the main contribution, without detailed discussion of limitations in the provided text. This paper is centrally about endometriosis — it summarizes phase III evidence that elagolix reduces endometriosis-associated pain symptoms.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (1)
Cited by (7)
- The Multifactorial Pathogenesis of Endometriosis: A Narrative Review Integrating Hormonal, Immune, and Microbiome Aspects 2025
- Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment? 2023
- Therapeutic effects of melatonin on endometriosis, targeting molecular pathways: Current knowledge and future perspective 2023
- Breaking the silence: The role of extracellular vesicles in unraveling the diagnosis and treatment of endometriosis 2023
- Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 2021
- NAT2 gene polymorphisms and endometriosis risk: A PRISMA-compliant meta-analysis 2019
- Elagolix for endometriosis: all that glitters is not gold 2018
Source provenance
- europepmc
- last seen: 2026-06-12T06:13:51.797165+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:20:25.745717+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00